Abstract: Purpose/Background: Clozapine is associated with hematological abnormalities, notably neutropenia, which may progress to agranulocytosis. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been used to reduce the frequency and duration of clozapine-associated neutropenia. This review aims to explore the use, efficacy, and tolerability of these cytokines in the treatment of clozapine-associated agranulocytosis.
C lozapine remains the criterion standard treatment for treatmentresistant schizophrenia. 1, 2 However, the use of clozapine is restricted in part because of its risk of inducing neutropenia, which may progress to agranulocytosis unless clozapine is promptly withdrawn. The cumulative incidence of clozapine-induced neutropenia (defined as an absolute neutrophil count [ANC] of <1.5 Â 10 9 cells/L) is 2.7% during the first year of use. 3 The cumulative incidence of clozapine-induced agranulocytosis (defined as an ANC of <0.5 Â 10 9 cells/L) is 0.8% at 1 year and 0.91 % at 18 months, 4 with the highest incidence at 6 to 18 weeks after commencing clozapine. 5 Clozapine use is accompanied by the requirement for regular full blood count monitoring in many countries, and if the total leukocyte and/or neutrophil counts indicate the development of neutropenia or agranulocytosis, clear criteria exist for drug withdrawal. The strategy combined with modern treatment options has largely prevented deaths from this serious adverse reaction; the mortality rate from clozapine-induced agranulocytosis is estimated to be 0.01% to 0.03% (case fatality rate, 2.2% to 4.2%). 6 In most countries, 7 when neutropenia occurs during clozapine treatment, clozapine must be discontinued. Depending on a patient's clinical state, management may be supportive with daily monitoring of the full blood count until the neutrophil count normalizes, or may involve the administration of antibiotics if there is a febrile neutropenia. Granulocyte colony-stimulating factors (G-CSFs) and granulocyte-macrophage colony-stimulating factors (GM-CSFs) have been used to treat clozapine-associated neutropenia. Both agents are typically administered during chemotherapy to reduce the incidence or the duration of neutropenia. 8, 9 They stimulate proliferation and differentiation of committed myeloid progenitor cells in the bone marrow. 10 Granulocyte colony-stimulating factors have supplanted the use of GM-CSF in recent years. Although both agents stimulate granulocyte production, G-CSF also shortens the maturation phase from progenitor cells to the neutrophil granulocyte, further increasing the peripheral neutrophil count. 11 Filgrastim and lenograstim are the most commonly used G-CSFs and are administered by subcutaneous injection. They both have short plasma half-lives; lenograstim t 1/2 is approximately 3 hours 12 and filgrastim t 1/2 is approximately 3.5hours, 13 and they are excreted renally.
Both G-CSF and GM-CSF have been used increasingly to treat clozapine-induced agranulocytosis. 14, 15 However, knowledge of their use in clozapine patients is limited. Their use in the treatment of agranulocytosis induced by nonchemotherapeutic agents has been reviewed, 16 but no similar review of their use for clozapine-associated agranulocytosis has been performed.
AIMS
We aimed to review the literature to investigate the effect of G-CSFs and GM-CSFs in reducing the duration of clozapine-associated agranulocytosis, to describe the doses of G-CSF used, and to review the tolerability of these agents.
METHODS
We performed a literature search to identify peer-reviewed interventional and observational studies, case series, and case reports until August 2016, investigating or describing G-CSF or GM-CSF as a treatment for clozapine-associated agranulocytosis. This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Metaanalysis standard. 17 
Inclusion Criteria
Studies and case reports of patients (no age restrictions) who were treated with G-CSF or GM-CSF for clozapine-associated agranulocytosis (with an ANC of <0.5 Â 10 9 cells/L), including patients who developed a neutropenia during rechallenge. For those cases of neutropenia with an ANC of less than 0.1 Â 10 9 cells/L, we described it as severe agranulocytosis, to distinguish a condition where an individual is at an increased risk of morbidity and mortality from infections, and to make it distinct from agranulocytosis (ANC of <0.5 Â 10 9 cells/L).
18

Exclusion Criteria
Studies were excluded if G-CSF or GM-CSF was used to support the maintenance of clozapine treatment during chemotherapy, if there was insufficient laboratory data to permit further evaluation of the report, or if they described a neutropenia with an ANC of greater than 0.5 Â 10 9 cells/L or with an ANC of greater than 1.5 Â 10 9 cells/L.
Information Sources and Searches
Two independent reviewers (J.L. and S.M.) performed an electronic search using PubMed, Medline, Scopus, EMBASE, and Google Scholar from inception until August 2016. The following search terms were used, alone and in combination: "granulocyte colony-stimulating factor," "granulocyte-macrophage colony-stimulating," "GCSF," "G-CSF," "GMCSF," or "GM-CSF," and "clozapine," "clozaril," "denzapine," "Zaponex," or "leponex." In addition, the reference lists of the retrieved articles and relevant review articles were examined for further reports.
Study Selection and Exclusion
All extracted reports were examined independently by 2 authors (J.L. and S.M.), and a list of full-text articles was established. Authors were contacted for clarification where necessary. There were 29 qualifying reports, 7 of which were case series and 22 were case reports. In total, 40 patients were identified who received G-CSF or GM-CSF as treatment for clozapineassociated agranulocytosis.
Primary and Secondary Outcomes
The primary outcome was the time for neutrophil recovery after starting G-CSF (as defined by recovery either within the normal range of a local laboratory or an ANC of >2.0 Â 10 9 cells/L). For secondary outcomes, we examined associations between neutrophil recovery time and the nadir neutrophil count (specifically the occurrence of agranulocytosis), the type of G-CSF or GM-CSF used, and the cumulative dose of G-CSF or GM-CSF used. The tolerability of G-CSF and GM-CSF was assessed, and outcomes including mortality due to complications secondary to neutropenia or agranulocytosis were recorded. The incidence of rebound leukocytosis (as defined by each study or a white cell count (WCC) of >10.0 Â 10 9 /L) was recorded, and associations between leukocytosis as well as dose and duration of G-CSF or GM-CSF use were assessed.
Data Extraction
The following information was extracted where possible: demographic and clinical characteristics of the patients, mean clozapine dosage (milligram per day) at the time of the neutropenic event, and duration of clozapine therapy before the onset of neutropenia, plasma clozapine concentrations-reported preneutropenia, nadir neutrophil count, neutropenia before the use of G-CSF or GM-CSF, neutropenia after the administration of G-CSF or GM-CSF, G-CSF or GM-CSF use, and total duration of neutropenia, antibiotic use, adverse effects associated with G-CSF or GM-CSF, and rebound leukocytosis associated with G-CSF or GM-CSF use.
RESULTS
Study Selection, Study, and Participant Characteristics
The study selection process, search results, and reasons for exclusion are given in Figure 1 .
The initial search yielded 766 references. After checking titles and abstracts, 57 full texts were screened and 29 of these (40 patients) were included for data extraction. 15, All were case series or reports; no interventional or observational studies were identified.
Acute Treatment With G-CSF for Clozapine-Associated Neutropenia or Agranulocytosis
The demographic and clinical characteristics of the group are shown in Table 1 . Twenty-seven patients (67.5% of total population) had a severe agranulocytosis, with an ANC of less than 0.1 Â 10 9 cells/L. Nine patients (39% of those in whom a clozapine first treatment or rechallenge status was reported) had developed a further neutropenia during clozapine rechallenge. There was insufficient data in relation to plasma clozapine concentrations to report in this review.
Clozapine was discontinued in all patients at onset of neutropenia. Antibiotics were administered to 21 patients. Bone marrow aspiration was performed in 11 patients (55% of those cases in which bone marrow aspiration was reported to be performed or not). Twenty-three patients (97.5% of those in whom G-CSF type was specified) were treated with filgrastim, whereas 1 patient was treated with sargramostim. The outcome characteristics of G-CSF or GM-CSF use are described in Table 2 . There were no deaths recorded.
The median time to neutrophil recovery was 7 days for all patients. For those with an ANC of 0.1 to 0.5 Â 10 9 cells/L, the median duration of neutrophil recovery time was 6 days. The mean (SD) total dose of filgrastim used was 399 (198) mcg (dose range, 125-900 mcg). There was no significant difference in mean time to neutrophil recovery between those treated with a lower daily dose of filgrastim (ie, 5 mcg/kg per day or less; n = 4; 7.0 ± 1.4 days) compared with those treated with 10 mcg/kg per day (n = 3; 6.3 [3.5] days; t = 0.352; P = 0.739). The dose of filgrastim used was not significantly correlated with the time to neutrophil recovery (r = 0.554; P = 0.050) after its administration, controlling for concurrent antibiotic use, baseline neutrophil count, and duration of neutropenia before G-CSF administration.
Adverse Events
No adverse reactions to G-CSF or GM-CSF were reported in the 29 cases (93.5% of those in whom reports referred to the presence or absence of adverse events). One female patient developed a thrombocytosis with clinical signs of deep vein thrombosis 43 after 7 days of treatment with G-CSF at a dose of 300 mcg/d (with a maximum platelet count of 800 Â 10 9 /L). The platelet count normalized 7 days after the discontinuation of G-CSF, with no further evidence of thrombosis. 43 Another patient, 42 a 30-year-old man, developed a right middle cerebral artery infarct after 3 days of treatment with GM-CSF 300 mcg/d (ANC of 0.1 Â 10 9 cells/L). 42 The activated partial thromboplastin time was prolonged at 39 seconds (normal range, <36 seconds), with a normal prothrombin time. There were no reports of bony or musculoskeletal pain, fever, headache, arthritic flare ups, or splenomegaly. No deaths occurred. Ten (46% of those cases in whom WCC were reported after G-CSF or GM-CSF use) of the patients had evidence of a rebound leukocytosis. For 11 of these cases, the average time to normalization of the leukocytosis (as defined by each study or a WCC <10.0 Â 10 9 /L) was 11.6 (15.5) days (range, 0-50 days). No adverse events were reported in association with these events. The average dose of filgrastim used was not significantly associated with the occurrence of leukocytosis (mean [SD] dose, 540.0 [270.6] mcg) in those with a leukocytosis (n = 7) compared with a mean (SD) dose of 411.4 (144.6) mcg in those with no leukocytosis (n = 7; t = 1.109; P = 0.289). Furthermore, the average duration of G-CSF use was not significantly associated with the occurrence of leukocytosis mean (SD) of 7.9 (3.0) days in those with leukocytosis compared with a mean (SD) of 7.3 (3.1) days in those with no leukocytosis (t = 0.434; P = 0.669).
DISCUSSION
In this, the first systematic review of the use of G-CSF for the treatment of clozapine-associated agranulocytosis, we identify that G-CSF treatment may be beneficial for patients in aiding with neutrophil recovery after the discontinuation of clozapine.
Granulocyte Colony-Stimulating Factor for Acute Treatment of Clozapine-Associated Agranulocytosis
The median time to neutrophil recovery in agranulocytosis after the administration of G-CSF was 7.0 days. This is shorter than the 12-day median duration of neutropenia recovery associated ; for case reports published since 1990). 16 Thus, the use of G-CSF in clozapine-associated neutropenia may shorten the duration of neutropenia by half and is notably less than the previously reported duration of clozapineassociated agranulocytosis (defined by ANC of <0.5 Â 10   9 ) not treated with G-CSF of 14 to 21 days. 15 Given that the duration of agranulocytosis is an important prognostic factor in druginduced agranulocytosis, 47 our finding of a duration of neutrophil recovery with G-CSF use of 7 days is clinically significant and suggests that G-CSF use should be more prominently considered for those with clozapine-associated agranulocytosis.
For those with severe agranulocytosis (ANC of <0.1 Â 10 9 cells/L), the mean (SD) time to neutrophil recovery after the administration of G-CSF was 7.7 (3.1) days and is comparable with the recovery time identified in a systematic review of case reports in which G-CSF was used to treat noncytotoxic drug-induced agranulocytosis (all drugs and not just clozapine; defined as an ANC of <0.1 Â 10 9 cells/L; mean [SD], 7.7 [5.1] days; n = 100 cases). 16 Our findings for an enhanced neutrophil recovery time with the use of G-CSF in severe agranulocytosis mirrors those for its use in agranulocytosis and severe agranulocytosis caused by other nonchemotherapeutic drugs and supporting the use of G-CSF in clozapine-associated agranulocytosis.
No deaths were reported in those who were treated with G-CSF. Granulocyte colony-stimulating factor or GM-CSF was well tolerated in all but 2 cases, 42, 43 with no severe adverse events identified in the others. In 1 case, GM-CSF was associated with arterial thrombosis. This case was associated with a prolonged activated partial thromboplastin time, which may be seen with antiphospholipid syndrome-though the patient was negative for anticardiolipin antibodies. A previous meta-analysis suggested that the use of GM-CSF compared with G-CSF was associated with an increased thrombotic risk, 48 although we were unable to investigate this because of the low numbers treated with GM-CSF. In the other case with an adverse reaction, a female patient treated with G-CSF developed a deep vein thrombosis. 43 Forty-six percent of patients had a rebound leukocytosis, after the administration of G-CSF for the treatment of clozapineassociated neutropenia, which lasted for an average duration of 12 days. This was not associated with the use of a higher mean dose of filgrastim or with a longer duration of G-CSF use. No overt clinical events were associated with this, including no reports of thrombotic events. However, given the high rate of occurrence of rebound leukocytosis, we recommend that clinicians continue to monitor white cell and platelet counts until normalization occurs and monitor patients for clinical evidence of venous thrombosis; for arterial thrombosis, monitoring for cardiac symptoms such as chest pain, neurological symptoms such as weakness, speech disturbance, confusion, and pain in the limbs, pulmonary edema, and hyperviscosity syndrome (eg, headache and blurred vision).
Limitations
The primary limitation is the possibility of publication bias. Most patients with clozapine-associated neutropenia/agranulocytosis are not reported in the literature, and it is likely that G-CSF is more widely used for the treatment of these episodes than is indicated here. It is possible that a bias toward reporting cases in which there is a favorable outcome after treatment with G-CSF may have occurred. It is also possible that cases in which adverse reactions or deaths have occurred are more likely to have been reported. There is no agreed method to assess the effect of publication bias in case reports. Further caution is required when interpreting the results, because data is lacking on numerous confounding factors which may have influenced when and why the decision was made to intervene with cytokine treatment, factors that are treated differently from 1 case to the next. Finally, as no comparative or observational studies were identified, we are unable to confirm that the duration of time to recovery is shortened, or that morbidity/mortality is reduced. The possibility remains that no treatment-discontinuing clozapine and allowing recovery to take its course-may be the most beneficial approach.
CONCLUSIONS
Our review demonstrates benefits for the use of G-CSF for patients with clozapine-associated agranulocytosis. A prospective placebo-controlled trial to establish the efficacy of G-CSF in clozapine-associated neutropenia/agranulocytosis would be the criterion standard study. The rarity of clozapine-induced neutropenia may make such a study impractical outside highly specialized centers. As such, observational and retrospective studies to establish the efficacy of G-CSF in clozapine-associated agranulocytosis would be the first choice for future research. Until such studies are conducted, this review of the available evidence suggests that G-CSF may be a valuable tool in the treatment of clozapineassociated agranulocytosis. However, the possibility of publication bias toward favorable outcomes cannot be ruled out.
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